MedPath
HSA Approval

DEVODIL 200 TABLET 200 mg

SIN09937P

DEVODIL 200 TABLET 200 mg

DEVODIL 200 TABLET 200 mg

August 7, 1998

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

**Dosage** In the treatment of schizophrenia initial doses of 200 to 400mg twice daily by mouth may be given, increased if necessary up to a maximum of 1,2g twice daily. Usual maintenance doses are 400 to 800mg daily by mouth. The usual dose of Devodil in the treatment of nausea, vomiting is 150 to 300mg daily in divided doses.

ORAL

Medical Information

**Indications** Devodil is indicated for the treatment of psychosomatic components of organic diseases, e.g., nausea, vomiting; and acute or chronic psychiatric disorders.

**Contra-indications** Devodil is contra-indicated in patients with pheochromocytoma and during pregnancy.

N05AL01

sulpiride

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

REMEDICA LTD

Active Ingredients

SULPIRIDE

200 mg

Sulpiride

Documents

Package Inserts

Devodil tablets PI.pdf

Approved: March 14, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.